The screen of analogs of PCs NCGC607 and NCGC758 (Fig. 2D) captured thirteen active compounds related to the NCGC607 (salicylic acid derivative) scaffold, including NCGC607 itself, and three active compounds with structural similarity to the NCGC758 (pyrazolopyrimidine) scaffold, including the investigational drug LTI-291/BIA 28-6156, which is currently being evaluated in a clinical trial for GBA1-PD (SI Appendix, Figs. S6A and S7) (75, 76). Here, GBA1 is linked to Parkinson disease.